Stone Crest Wealth Management, Inc. Viridian Therapeutics, Inc.\De Transaction History
Stone Crest Wealth Management, Inc.
- $116 Billion
- Q1 2024
A detailed history of Stone Crest Wealth Management, Inc. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Stone Crest Wealth Management, Inc. holds 27,675 shares of VRDN stock, worth $340,956. This represents 0.42% of its overall portfolio holdings.
Number of Shares
27,675
Previous 27,791
0.42%
Holding current value
$340,956
Previous $605 Million
19.94%
% of portfolio
0.42%
Previous 0.58%
Shares
2 transactions
Others Institutions Holding VRDN
# of Institutions
143Shares Held
62.1MCall Options Held
160KPut Options Held
354K-
Paradigm Biocapital Advisors LP New York, NY5.03MShares$62 Million3.3% of portfolio
-
State Street Corp Boston, MA4.49MShares$55.3 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$47.8 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.81MShares$47 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.66MShares$45.1 Million1.34% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $491M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...